Andexanet Alfa (Andexxa

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Risk Factors Associated with Thrombus Development Following Pharmacologic Anticoagulation Reversal with Coagulation Factor Xa [Recombinant], Inactivated-zhzo.Hospital pharmacy · 2026
   Article
2. Visualized Efficacy of Andexanet Alfa in an Elderly Trauma Patient with an Unstable Pelvic Fracture.JMA journal · 2024
   Article
3. Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding.Nature communications · 2024
   Article
4. Non-traumatic Spinal Subdural Hemorrhage Associated With Rivaroxaban Use.Cureus · 2024
   Article
5. Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage.CNS drugs · 2023
   Review
6. Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice.Pharmacy (Basel, Switzerland) · 2023
   Review
7. Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists.Global cardiology science & practice · 2022
   Article
8. "Accessory After the Factors": A Rare Case of an Acquired Factor VIII Inhibitor in a 75-Year-Old Man on Rivaroxaban.Cureus · 2021
   Article
9. Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty.Emergency medicine international · 2021
   Article
10. Institutional Experience of Using Andexanet Alfa.Cureus · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as